Riverwater Partners released its Q3 2025 investor letter for the Micro Opportunities Strategy, reporting positive returns but lagging behind the benchmark due to a strong market rally. The strategy focuses on quality companies in a volatile market. IRADIMED CORPORATION (NASDAQ:IRMD) was highlighted as a top performer with significant growth.

IRADIMED CORPORATION (NASDAQ:IRMD) saw a one-month return of 13.54% and shares gained 84.62% over the last 52 weeks. The company’s stock closed at $97.02 per share on December 15, 2025, with a market capitalization of $1.244 billion. Riverwater Partners praised IRADIMED’s growth potential in the medical technology sector due to its market share and recurring revenue model.

While IRADIMED CORPORATION (NASDAQ:IRMD) is not among the 30 most popular stocks among hedge funds, it reported record revenue of $21.2 million in Q3 2025, marking a 16% increase from the previous year. Despite its potential, some believe certain AI stocks offer greater upside with less downside risk. For more investment insights, check out hedge fund investor letters Q3 2025.

In a separate article, IRADIMED CORPORATION (NASDAQ:IRMD) was highlighted as one of the best small-cap stocks with huge potential beyond the AI trade. Investors can explore more investor letters from hedge funds and leading investors for additional insights and opportunities.

Read more at Yahoo Finance: What Makes IRADIMED CORPORATION (IRMD) a Compelling Opportunity?